SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review

Table 2

Overview of the neurological protective studies.

Authors	Treatment	Size	Duration	Population		Outcome
				Clinical	Animal
Takakura et al. [19]	Ipragliflozin	44	12 weeks		SDT fatty and SD rats	Reduced prolonged peak latency; Improved MNCV
Tsuboi et al. [25]	Vildagliptin	30	18 weeks		Goto-Kakizaki (GK) DM rats	Improved nerve conduction velocity and atrophy
Davidson et al. [26]	Alogliptin	32	12 weeks		STZ-induced DM rats	Improved nerve conduction velocity
Kolaczynski et al. [27]	Vildagliptin	16321	—	DM II		Lower incidence of neuropathy
Da Silva et al. [28]	Sitagliptin	30	1 year	DM II		No benefit on nerve conduction
Jaiswal et al. [29]	Exenatide	42	1.5 years	DM II; Mild-to-moderate DPN		No effect on neuropathy

DM II: diabetes mellitus type 2; MNCV: motor neuron conduction velocity; DPN: diabetic peripheral neuropathy; DM: diabetes mellitus; SD: Sprague Dawley; SDT: spontaneously diabetic Torii; STZ: streptozotocin.